Cart
sales@molnova.com
NBD-Cl
CAS No. 10199-89-0
NBD-Cl( NBD chloride )
Catalog No. M23226 CAS No. 10199-89-0
NBD-Cl is a nonfluorescent compound that becomes highly fluorescent after reaction with amino or thiol groups.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 27 | In Stock |
|
| 1G | 36 | In Stock |
|
Biological Information
-
Product NameNBD-Cl
-
NoteResearch use only, not for human use.
-
Brief DescriptionNBD-Cl is a nonfluorescent compound that becomes highly fluorescent after reaction with amino or thiol groups.
-
DescriptionNBD-Cl is a nonfluorescent compound that becomes highly fluorescent after reaction with amino or thiol groups.
-
In VitroNBD-Cl (NBD chloride) forms highly fluorescent derivatives for detection of all the protein amino acids. In addition, NBD-Cl provides a simple and sensitive method for determination of N-terminal amino acids. The differences in intensity and color of fluorescence can be used to advantage to identify prolyl peptides.
-
In Vivo——
-
SynonymsNBD chloride
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number10199-89-0
-
Formula Weight199.55
-
Molecular FormulaC6H2ClN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (501.13 mM)
-
SMILESO=[N+](C1=CC=C(Cl)C2=NON=C21)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Glycogen phosphoryla...
Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.
-
8-Methyl Chrysophano...
8-Methyl Chrysophanol is an anthraquinone isolated from the bark of?Senna macranth.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
